Breast Cancer Clinical Trial
Official title:
High Intensity Focused Ultrasound Guided by MRI as Thermic Destruction in Primitive Small Size Breast Cancer. Phase II Pilot Study : Effectiveness and Procedures Standardization
This is a non-randomized, prospective phase II trial evaluating an innovative treatment, focused MRI-guided ultrasound, as thermic destruction in primitive small size breast cancer.
Conservative Breast Treatment (BCT) :
The reference treatment for patients with stage T1 breast cancer is a partial mastectomy
followed by radiotherapy (breast). This is a conservative treatment (BCT). Indeed, the
survival results of this combined treatment are equivalent to those observed after a total
mastectomy alone and is an aesthetically and psychologically more acceptable proposition for
patients.
Adjuvant radiotherapy is an essential component of the success of conservative therapy most
likely due to the impossibility of surgical treatment of removing all microscopically viable
cancer cells. Indeed, in the absence of radiotherapy, partial mastectomy shows a local
recurrence rate of 20-40% in case of N0 and 25-50% in case of N + on long-term follow-up
data.
The results of the literature are very variable according to the length of the follow-up and
the population studied but the adjuvant radiotherapy clearly allows to increase the rate of
local control.
It reduces local recurrences to 10% at 12 years in the case of radiotherapy in the breast and
6% in case of boost on the tumor area.
The high sensitivity of breast MRI and emerging issues. The development of breast MRI
revealed the incidental discovery of 10 to 40% of additional breast cancer in patients
initially explored by mammography and ultrasound standards. These cancers discovered at early
stages and of small size complicate the strategy of local management and incite to develop
techniques alternative to the surgery.
Several minimally invasive treatments for the local treatment of breast cancers are being
studied: BLES (Breast Lesion Excision Sample), cryotherapy, radiofrequency, laser and
microwaves. Among them, focused ultrasound offers a completely non-invasive heat ablation
technique.
High intensity focused ultrasound (FUS) and magnetic resonance imaging (MRI) guidance =
FUS-MRI High intensity focused ultrasound thermal ablation is an attractive treatment
modality for solid tumors because it does not require incision. Moreover, coupled with
magnetic resonance, it offers precise targeting and control destruction.
An ablation procedure begins with the acquisition of a series of MRI images centered on the
organ to be treated. The radiologist loads the images onto the processing machine and
identifies the target volume to be destroyed by segmenting it from the MRI images. The
console provides a treatment plan with the necessary parameters to efficiently process the
defined region.
High intensity focussed ultrasonic destruction is possible due to the elevation of
temperature at the focal point. By analogy, one can compare the technique to the use of a
magnifying glass to focus the sun's rays and trigger a flame. In ultrasound diagnostic
ultrasound is used without convergence of beams. In the therapeutic application, it is the
focusing at a point and the use of high intensities which make it possible to deliver energy
in the form of heat. This step is called "sonication". Sonication heats the tissue between 65
and 85 ° C in the well-defined region of the focal point and causes tissue
thermo-coagulation.
MRI images acquired during heating allow real-time monitoring of the rise in temperature.
This makes it possible to check the position of the sonication and the size of the zone thus
coagulated. The sonications are thus repeated at multiple adjacent points to cover the
prescribed ablation volume.
This combination of FUS-MRI has already shown convincing results on bone, prostate and
uterine fibroid tumors, so the hypothesis is that it has a potential interest in the
conservative treatment of breast cancer.
The Ex-Ablate 2000 system (trade name) It is a machine incorporating FUS-MRI technology. It
consists of a high intensity focused ultrasound transducer mounted in the MRI examination
table.
With its precision and unique ability to follow ablation, Ex-Ablate has been used in many
tumor contexts and has demonstrated its ability to provide significant tumor destruction on
small volumes.
On the breast, the system showed promising results in several Phase II protocols on the
treatment of breast tumors with good aesthetic results and no major toxicity.
These arguments justify the choice of using Ex-Ablate as a means of thermic destruction for
small size breast cancer.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |